• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Introduction to 1,8,15,22,29,36-Hexaazacyclodotetracontane-2,9,16,23,30,37-Hexaone (CAS No. 865-14-5)

1,8,15,22,29,36-Hexaazacyclodotetracontane-2,9,16,23,30,37-hexaone (CAS No. 865-14-5) is a complex macrocyclic compound that has garnered significant attention in the fields of chemistry and medicinal research due to its unique structural properties and potential applications. This compound belongs to the class of macrocyclic polyamines and is characterized by its six nitrogen atoms and six ketone groups arranged in a cyclic structure. The intricate arrangement of these functional groups endows the molecule with remarkable stability and reactivity, making it a valuable candidate for various scientific investigations.

The synthesis of 1,8,15,22,29,36-hexaazacyclodotetracontane-2,9,16,23,30,37-hexaone is a challenging task that requires precise control over the formation of the macrocyclic ring. Recent advancements in synthetic chemistry have led to the development of efficient methodologies for its preparation. One notable approach involves the use of multicomponent reactions (MCRs), which allow for the simultaneous formation of multiple bonds and functional groups in a single step. This method not only simplifies the synthetic process but also enhances the yield and purity of the final product.

In terms of its physical and chemical properties, 1,8,15,22,29,36-hexaazacyclodotetracontane-2,9,16,23,30,37-hexaone exhibits high thermal stability and solubility in polar solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). These properties make it suitable for use in various analytical techniques and biological assays. Additionally, the compound's ability to form stable complexes with metal ions has been extensively studied. Research has shown that it can selectively bind to certain metal ions such as copper(II), zinc(II), and iron(III), which has implications for its use in metal ion sensing and catalysis.

The biological activity of 1,8,15,22,29,36-hexaazacyclodotetracontane-2,9,16,23,30,37-hexaone has also been a focus of recent studies. Preliminary investigations have indicated that this compound possesses antimicrobial properties against a range of bacterial strains. The mechanism by which it exerts these effects is thought to involve disruption of bacterial cell membranes or interference with essential metabolic pathways. Furthermore, studies have explored its potential as an antiviral agent against various viral infections. The compound's ability to inhibit viral replication has been attributed to its interaction with viral enzymes or host cell receptors.

In the realm of medicinal chemistry, 1,8,15,22,29,36-hexaazacyclodotetracontane-2，9，16，23，30，37-hexaone has shown promise as a lead compound for drug development. Its unique structure allows for the introduction of various functional groups through chemical modification techniques such as alkylation and acylation. These modifications can enhance the compound's pharmacological properties and improve its bioavailability and therapeutic efficacy. Current research efforts are focused on optimizing these derivatives for specific therapeutic applications.

Clinical trials involving derivatives of 1，8，15，22，29，36-hexaazacyclodotetracontane-2，9，16，23，30，37-hexaone are underway to evaluate their safety and efficacy in treating various diseases. Early results have been encouraging, with some derivatives demonstrating significant therapeutic potential in preclinical models of cancer and neurodegenerative disorders. These findings highlight the versatility and potential impact of this compound in advancing medical treatments.

In conclusion, 1，8，15，22，29，36-hexaazacyclodotetracontane-2，9，16，23，30，37-hexaone (CAS No. 865-14-5) is a multifaceted compound with a wide range of applications in chemistry and medicine. Its unique structural features and biological activities make it an important subject of ongoing research. As new synthetic methods and biological insights continue to emerge, 1，8，15，22，29，36-hexaazacyclodotetracontane-2，9，16，23，30，37-hexaone is poised to play a significant role in advancing scientific knowledge and developing innovative solutions for various challenges in healthcare.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)